advanced lung cancer
Conditions
Interventions
to evaluate the proportion of renal toxicity in cisplatin-based chemotherapy with short hydration
Sponsors
Okayama Lung Cancer Study Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: pathologically proven squamous cell carcinoma stage IV or stage III without suitability for curative treatment aged 75 or younger measurable tumor sites no prior chemotherapy no prior systemic anticancer therapy including palliative brain or bone irradiation within 2 weeks of proposed entry to this trial ECOG PS of 0 to 1 appropriate organ function acquisition of written informed consent
Exclusion criteria
Exclusion criteria: pts with active co-morbidities including severe conditions of heart diseases, gastric ulcers, infections, uncontrollable diabetes, psychlogicai diseases, hypertension, active interstitial and hearing loss. pts with active other cancers detected within the past 3 years. pts with massive pleural and cardiac effusion and ascites that need to be immediately treated pts with symptomatic brain metastases pts who will receive CDDP of less than 60 mg/m²/day
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| feasibility of cisplatin-based chemotherapy with short hydration | — |
Countries
Japan
Contacts
Public ContactKatsuyuki Hotta
Okayama University Hospital Department of Respiratory Medicine
Outcome results
None listed